Case Letter

Nevus Sebaceus With Novel HRAS Sequence Variant Mutation Misdiagnosed as Alopecia Areata

Author and Disclosure Information

 

References

Nevus sebaceus typically is caused by a sporadic mutation, though familial cases have been reported.1 Additionally, germline HRAS mutations can lead to Costello syndrome, an autosomal-dominant disorder characterized by short stature; intellectual disabilities; coarse facial features; facial and perianal papillomata; cardiac defects; loose skin; joint hyperflexibility; and an increased risk for malignant tumors including rhabdomyosarcoma, neuroblastoma, and transitional cell carcinoma of the bladder.6

The diagnosis of NS often can be made clinically but can be difficult to confirm in underdeveloped lesions in young children. The differential diagnosis can include alopecia areata, aplasia cutis congenita, juvenile xanthogranuloma, epidermal nevus, de novo syringocystadenoma papilliferum, and solitary mastocytoma.1 Nevus sebaceus can be associated with 4 additional syndromes: Schimmelpenning syndrome; phacomatosis pigmentokeratotica; didymosis aplasticosebacea; and SCALP (sebaceus nevus, central nervous system malformations, aplasia cutis congenital, limbal dermoid, pigmented nevus) syndrome.1 Approximately 7% of NS cases may be associated with Schimmelpenning-Feuerstein-Mims (SFM) syndrome, a more severe condition that leads to systemic involvement and abnormalities in the neurological, ophthalmological, cardiovascular, genitourological, and skeletal systems.1,3 Phacomatosis pigmentokeratotica has speckled lentiginous nevi, as well as abnormalities in the neurological, ophthalmological, cardiovascular, genitourological, and skeletal systems.1 Didymosis aplasticosebacea is the concurrence of NS and aplasia cutis congenita.

The definitive treatment of NS is surgical excision. Alternative therapies include photodynamic therapy, fractional laser resurfacing, and dermabrasion; these are not definitive treatments, and patients must be monitored for the development of secondary neoplasms. Multiple variables must be considered when determining treatment, including patient age, risk potential for malignancy, and surgery-associated risks.1 In our patient, given the extent of the lesions, active observation and follow-up was agreed upon for management.

This case demonstrates the importance of considering NS as an alternative diagnosis when alopecia areata has been diagnosed in a child who is unresponsive to treatments. After the diagnosis of NS is confirmed, more serious associated syndromes should be ruled out, and treatment should be tailored to each case.

Pages

Recommended Reading

Limited treatment options exist for brittle nail syndrome
MDedge Dermatology
Habit Reversal Therapy for Skin Picking Disorder
MDedge Dermatology
Treatment of Frontal Fibrosing Alopecia in Black Patients: A Systematic Review 
MDedge Dermatology
The earlier baricitinib for severe alopecia areata is started, the better
MDedge Dermatology
Alzheimer’s drug may ease hair pulling, skin-picking disorders
MDedge Dermatology
Scalp Nodule Associated With Hair Loss
MDedge Dermatology
Polyurethane Tubing to Minimize Pain During Nail Injections
MDedge Dermatology
Cutaneous Signs of Malnutrition Secondary to Eating Disorders
MDedge Dermatology
Gray hair and aging: Could ‘stuck’ stem cells be to blame?
MDedge Dermatology
FDA puts partial hold on investigational alopecia areata drug deuruxolitinib
MDedge Dermatology